Revenue and Profit - Revenue for Q1 2022 reached ¥95,802,322.64, an increase of 114.26% compared to ¥44,712,533.27 in the same period last year[4] - Net profit attributable to shareholders was ¥19,529,827.85, up 352.57% from ¥4,315,275.49 year-on-year[4] - Basic earnings per share increased to ¥0.18, representing a growth of 260.00% compared to ¥0.05 in the previous year[4] - Operating profit for the quarter was ¥16,859,281.24, up from ¥3,433,329.27, reflecting a growth of approximately 390% year-over-year[33] - Net profit attributable to the parent company was ¥19,529,827.85, compared to ¥4,315,275.49 in the previous year, marking an increase of about 353%[33] - Basic and diluted earnings per share for the quarter were both ¥0.18, compared to ¥0.05 in the same period last year, representing a 260% increase[36] Expenses and Costs - Research and development expenses surged to ¥44,014,040.32, a 263.32% increase from ¥12,114,330.77 in the same period last year[12] - The total operating costs for the quarter were ¥80,721,016.07, up from ¥41,034,563.58, which is an increase of about 97% year-over-year[30] - The company reported a financial expense of -¥11,046,988.42, a significant improvement compared to ¥260,929.15 in the previous year[30] Cash Flow and Liquidity - The net cash flow from operating activities was -¥33,055,022.37, a decline of 545.00% compared to -¥5,124,775.28 in the previous year[12] - Operating cash inflow for the period was CNY 104,198,451.75, compared to CNY 47,901,106.52 in the previous period, indicating a significant increase[37] - Cash outflow from operating activities totaled CNY 137,253,474.12, up from CNY 53,025,881.80 in the previous period, resulting in a net cash flow from operating activities of CNY -33,055,022.37[37] - Cash outflow for investing activities was CNY 107,504,546.11, compared to CNY 89,178,749.68 in the previous period, leading to a net cash flow from investing activities of CNY -107,499,855.85[40] - Cash outflow from financing activities reached CNY 240,411,585.24, significantly higher than CNY 1,935,857.07 in the previous period, resulting in a net cash flow from financing activities of CNY -240,411,585.24[40] - The net increase in cash and cash equivalents was CNY -380,966,463.46, compared to CNY -74,547,033.01 in the previous period[40] - The ending balance of cash and cash equivalents was CNY -322,908,967.51, down from CNY 58,057,495.95 at the beginning of the period[40] Assets and Liabilities - Total assets decreased by 10.53% to ¥2,616,781,425.54 from ¥2,924,873,724.42 at the end of the previous year[4] - The total liabilities include short-term borrowings of ¥5,006,111.11 and accounts payable of ¥47,852,813.03, with accounts payable decreasing from ¥129,832,845.11[23] - Total liabilities decreased to ¥278,624,958.90 from ¥607,099,838.11, a reduction of about 54%[26] - The company's total equity increased to ¥2,338,156,466.64 from ¥2,317,773,886.31, reflecting a growth of approximately 0.9%[26] - The company reported a total of 1,888,798,999.70 in current assets, down from 2,225,554,608.43, a decrease of approximately 15%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,500, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Shao Chunnan, holds 18.72% of the shares, amounting to 20,250,000 shares[16] - The company has no preferred shareholders and no changes in restricted shares during the reporting period[20] Other Financial Information - The company received government subsidies amounting to ¥6,015,474.42 during the reporting period[7] - The company reported a significant increase in accounts receivable, which rose by 141.23% to ¥1,100,000.00 from ¥456,000.00 at the beginning of the period[8] - Accounts receivable increased to ¥99,707,532.34 from ¥76,755,728.68, reflecting a growth of about 30%[20] - Inventory at the end of the reporting period is ¥31,018,704.39, up from ¥22,851,850.91, indicating an increase of approximately 36%[23] - The company received CNY 15,809,390.72 in tax refunds during the period, which was not reported in the previous period[37] - The company paid CNY 49,847,041.33 to employees, an increase from CNY 27,929,025.81 in the previous period[37] Audit and Reporting - The first quarter report was not audited, indicating a need for caution in interpreting the financial results[41]
百诚医药(301096) - 2022 Q1 - 季度财报